Fulgent Genetics, Inc.
FLGT Healthcare Diagnostics & Research
Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 4.38%, EPS fell 69.4% and free cash flow grew 25.4%, each against the same quarter a year earlier.
Follow FLGT
Fulgent Genetics, Inc. (FLGT) EV/Sales
As of 16 October 2026, Fulgent Genetics, Inc. (FLGT) trades at a EV/Sales of 1.0×. Over the past ten years it has ranged from 0.0× (September 2016) to 24.7× (August 2020); the current reading is higher than 14% of that period. That is below the Diagnostics & Research industry median of 5.5× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.5× | 34.91% |
| FY2024 | 1.1× | (30.13%) |
| FY2023 | 1.6× | 140.50% |
| FY2022 | 0.7× | (73.52%) |
| FY2021 | 2.5× | 19.50% |
| FY2020 | 2.1× | (67.86%) |
| FY2019 | 6.6× | 445.60% |
| FY2018 | 1.2× | (53.10%) |
| FY2017 | 2.6× | (64.11%) |
| FY2016 | 7.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.0× | 42.09% |
| Mar 2026 | 0.7× | (51.89%) |
| Dec 2025 | 1.5× | 41.89% |
| Sep 2025 | 1.1× | (2.52%) |
| 39 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MYGN Myriad Genetics, Inc. compare | 0.5× |
| FLGT Fulgent Genetics, Inc. | 1.0× |
| CSTL Castle Biosciences, Inc. compare | 2.0× |
| OPK OPKO Health, Inc. compare | 2.0× |
| BDSX Biodesix, Inc. compare | 2.5× |
| XGN Exagen Inc. compare | 2.6× |
| NEO NeoGenomics, Inc. compare | 3.4× |
| WGS GeneDx Holdings Corp. compare | 4.1× |
| PSNL Personalis, Inc. compare | 20.9× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)